指南与共识湿疹皮炎与荨麻疹

立场声明:特应性皮炎中的外用钙调神经磷酸酶抑制剂

Position statement: topical calcineurin inhibitors in atopic dermatitis.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2018-11-06

由六名欧洲皮肤病专家采用改良德尔菲法(2017年6月网络会议、7-9月两轮盲法投票、11月面对面会议)形成共识,共定义并验证25条共识声明,其中8条关于特应性皮炎背景、17条关于外用钙调神经磷酸酶抑制剂(他克莫司软膏与吡美莫司乳膏)的使用。结论认为外用钙调神经磷酸酶抑制剂是特应性皮炎的合适治疗,具体选择应基于区分他克莫司与吡美莫司的因素。

要点

  • 共形成25条共识声明:8条关于特应性皮炎背景,17条关于外用钙调神经磷酸酶抑制剂。
  • 17条声明涵盖作用机制、治疗指征、成人与儿童疗效、药代动力学、不良事件发生率及安全性。
  • 热点话题包括乳膏与软膏、剂量、接触过敏、烧灼感处理、重叠感染和疫苗接种关注。

核心结论

  • 外用钙调神经磷酸酶抑制剂是特应性皮炎的合适治疗。
  • 具体外用钙调神经磷酸酶抑制剂的选择应基于区分他克莫司与吡美莫司的因素。

研究设计与样本

  • 采用改良德尔菲法的共识项目,由来自不同欧洲国家的六名专家皮肤科医生参与。
  • 共识过程包括三个阶段:2017年6月网络会议、2017年7-9月两轮在线盲法德尔菲投票、2017年11月面对面会议。

主要发现

  • 共定义并验证25条共识声明:8条关于特应性皮炎的一般背景,17条关于外用钙调神经磷酸酶抑制剂在特应性皮炎中的使用。
  • 17条声明涵盖作用机制与治疗指征、成人与儿童特应性皮炎患者的疗效、药代动力学、不良事件发生率及安全性关注。
  • 外用钙调神经磷酸酶抑制剂治疗特应性皮炎的热点话题包括乳膏与软膏、剂量、外用钙调神经磷酸酶抑制剂接触过敏、烧灼感处理、重叠感染和疫苗接种关注。

关键数值与推荐

  • 共25条共识声明获得定义和验证,其中8条关于特应性皮炎背景、17条关于外用钙调神经磷酸酶抑制剂的使用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease in both adults and children. Whilst topical calcineurin inhibitors (TCIs), tacrolimus ointment and pimecrolimus cream, have proven efficacy for the treatment of AD, it is important to involve experts to obtain their opinion on its optimal treatment. OBJECTIVE: Using a modified Delphi approach, this project aimed to generate consensus amongst experts on the use of TCIs in the treatment of AD, with a focus on the differentiation between tacrolimus and pimecrolimus. METHODS: Six expert dermatologists from different European countries participated in this project based on their experience with AD and its treatment, which was evaluated by literature analysis and expert opinion. Consensus amongst the experts was generated using a modified Delphi approach, consisting of three distinct phases, during which a web meeting (June 2017), two online rounds of blinded Delphi voting (July-September 2017) and a face-to-face meeting (November 2017) were conducted. The consensus statements concerned two main topics: (i) Background of AD; and (ii) TCIs in AD. Hot topics in the treatment of AD not supported by meta-analysis, clinical trials or large observational studies were also discussed based on clinical experience. RESULTS: In total, 25 consensus statements were defined and validated: eight statements on the general background of AD and 17 statements on the use of TCIs in AD, including their mechanism of action and therapeutic indications in AD, efficacy in adult and paediatric AD patients, pharmacokinetics, incidence of adverse events and safety concerns. Hot topics on the use of TCIs for the treatment of AD included cream vs. ointment, dosages, TCIs contact allergy, burning sensation management, superinfection and vaccination concerns. CONCLUSION: Topical calcineurin inhibitors are a suitable therapy for AD, and selection of the specific TCI should be based on factors which differentiate tacrolimus from pimecrolimus.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Remitz A, De Pità O, Mota A, et al. Position statement: topical calcineurin inhibitors in atopic dermatitis. J Eur Acad Dermatol Venereol. 2018. PMID: 30288799. doi:10.1111/jdv.15272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。